WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018021772) FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/021772 International Application No.: PCT/KR2017/007933
Publication Date: 01.02.2018 International Filing Date: 24.07.2017
IPC:
A61K 9/28 (2006.01) ,A61K 9/50 (2006.01) ,A61K 9/20 (2006.01) ,A61K 31/4439 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
28
Dragees; Coated pills or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
50
Microcapsules
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Applicants: HANMI PHARM. CO., LTD.[KR/KR]; 214, Muha-ro, Paltan-myeon Hwaseong-si Gyeonggi-do 18536, KR
Inventors: KWON, Taek Kwan; KR
LEE, Kwang Young; KR
IM, Ho Taek; KR
KIM, Yong Il; KR
PARK, Jae Hyun; KR
WOO, Jong Soo; KR
Agent: LEE, Cheo Young; KR
CHANG, Je Hwan; KR
Priority Data:
10-2016-009423825.07.2016KR
Title (EN) FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
(FR) FORMULATION AYANT DES CARACTÉRISTIQUES AMÉLIORÉES DE LIBÉRATION DE MÉDICAMENT EN FONCTION DU PH, CONTENANT DE L'ÉSOMÉPRAZOLE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
(KO) 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
Abstract:
(EN) The present invention relates to a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention has remarkably improved pH-dependent drug-release characteristics of esomeprazole or the pharmaceutically acceptable salt thereof, and thus the release of esomeprazole or the pharmaceutically acceptable salt thereof can be started from a predetermined point in time after a desired lapse of time after the oral administration of the same, the release occurs for the desired period of time, and the release can also be completed after a predetermined lapse of time, such that, compared to those of other conventional formulations, excellent convenience and therapeutic effects for the patient can be expected.
(FR) La présente invention concerne une formulation pharmaceutique contenant de l'ésométprazole ou un sel pharmaceutiquement acceptable de celui-ci. La formulation pharmaceutique selon la présente invention présente des caractéristiques remarquablement améliorées de libération de médicament en fonction du pH de l'ésoméprazole ou du sel pharmaceutiquement acceptable de celui-ci, et ainsi la libération d'ésoméprazole ou d'un sel pharmaceutiquement acceptable de celui-ci peut être initiée à partir d'un moment souhaité après l'administration orale de celui-ci, la libération se produit pendant la période de temps souhaitée, et la libération peut également être achevée après un laps de temps prédéterminé, de telle sorte que, par rapport à ceux d'autres formulations classiques, il est possible d'obtenir d'excellents effets pratiques et thérapeutiques pour le patient.
(KO) 본 발명은 에스오메프라졸(Esomeprazole) 또는 약학적으로 허용가능한 그의 염을 포함하는 약제학적 제형에 대한 것으로, 본 발명에 따른 약제학적 제형은 에스오메프라졸 또는 약학적으로 허용가능한 그의 염의 pH-의존성 약물 방출 특성이 현저하게 개선되어, 경구 투여 후 목적하는 지연 시간이 경과한 특정 시간으로부터 에스오메프라졸 또는 약학적으로 허용가능한 그의 염의 방출이 시작되어, 목적하는 시간 동안 방출이 일어나고, 또한 특정 시간이 경과하면 방출이 완료될 수 있어, 종래 다른 제형과 비교하여 우수한 환자 편의성 및 치료 효과를 기대할 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)